Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors

Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors

Background. Immunotherapy represents one of the fundamental treatments in the management of some types of cancer, especially malignant melanoma. Toxicity derived from increased immune system activity can manifest in multiple organs and systems. We present a case of hematological toxicity, manifested...

Full description

Bibliographic Details
Main Authors: Alejandro Olivares-Hernández, Luis Figuero-Pérez, María A. Amores Martín, Lorena Bellido Hernández, Laura Mezquita, María del Rosario Vidal Tocino, Félix López Cadenas, Felipe Gómez-Caminero López, Roberto A. Escala-Cornejo, Juan Jesús Cruz Hernández
Format: Article
Language:English
Published: Hindawi Limited 2021-01-01
Series:Case Reports in Oncological Medicine
Online Access:http://dx.doi.org/10.1155/2021/6631859

Internet

http://dx.doi.org/10.1155/2021/6631859

Similar Items